21
Denosumab for Smoldering Multiple Myeloma
Condition(s):Smoldering Multiple MyelomaLast Updated:July 8, 2021Recruiting
Multiple Myeloma: 3359 Clinical Trials, Page 3 of 336
Hide Studies Not Open or Pending
22
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 7, 2022Recruiting
23
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 15, 2017Withdrawn
24
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
Condition(s):Multiple MyelomaLast Updated:January 6, 2022Not yet recruiting
25
Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 18, 2022Completed
26
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 29, 2020Terminated
27
Bone Pain in Multiple Myeloma- a Translational Study
Condition(s):Multiple MyelomaLast Updated:February 9, 2022Active, not recruiting
28
Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine
Condition(s):Multiple MyelomaLast Updated:June 30, 2022Recruiting
29
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Condition(s):Multiple Myeloma; Smoldering Multiple Myeloma; Monoclonal Gammopathy of Undetermined SignificanceLast Updated:June 9, 2022Recruiting
30
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:May 4, 2022Withdrawn